TNFRSF8 and neoplasm: The fourth clinical study is an open-label phase Ib/IIa study evaluating the biological activity of AFM13 in the elimination of CD30-positive tumor cells in patients with relapsed or refractory cutaneous lymphomas (ClinicalTrials.gov: NCT03192202).